chek2 1100delc
Recently Published Documents


TOTAL DOCUMENTS

94
(FIVE YEARS 1)

H-INDEX

28
(FIVE YEARS 0)

Breast Care ◽  
2021 ◽  
pp. 1-5
Author(s):  
Tahereh Soleimani ◽  
Abigail J. Engwall ◽  
Corrie Bourdon ◽  
Mohammad A. Torabi ◽  
Thais Fortes

Background: Breast cancer (BC) is the most common non-skin cancer affecting women but is extremely uncommon in the adolescent population. Genetic inheritance has been linked to <10% of BCs. CHEK2 is an uncommon genetic variant with a reported incidence of 0.3–1.6% in the general population and 4.9–5.7% in those with a family history of BC. Commonly, this mutation presents in females of European descent and is rare in North America. Case Presentation: A 19-year-old Caucasian female presented with breast pain and mass. She had an extensive family history of cancer, as well as a known CHEK2 gene mutation in 2 of her paternal aunts. Ultrasound and MRI confirmed a 4.5-cm mass with an enlarged right axillary lymph node. Image guided biopsy of the breast mass showed ER/PR-positive grade 1 invasive mucinous ductal cancer. Genetic testing confirmed an isolated CHEK2 mutation. After discussion by a multidisciplinary tumor board, the patient deferred bilateral mastectomy and underwent a right mastectomy with sentinel-lymph-node biopsy and immediate tissue-expander reconstruction. Final pathology confirmed ER/PR-positive Stage 1A (pT2 pN0 M0) invasive mucinous carcinoma. Chemotherapy was not recommended. Summary: Malignant adolescent breast masses are relatively rare and CHEK2 does not typically present at younger than 20 years of age. While there are many different differential diagnoses when evaluating an adolescent with a breast mass, we wish to increase providers’ suspicion of malignancy, specifically in those individuals who have a strong family history of BC and the CHEK2*1100delC mutation.


Cureus ◽  
2020 ◽  
Author(s):  
Quan D Nguyen ◽  
Anahita Tavana ◽  
Florentino Saenz Rios ◽  
Flavia E Posleman Monetto ◽  
Angelica S Robinson

2020 ◽  
Vol 112 (12) ◽  
pp. 1275-1279 ◽  
Author(s):  
Anne S Reiner ◽  
Mark E Robson ◽  
Lene Mellemkjær ◽  
Marc Tischkowitz ◽  
Esther M John ◽  
...  

Abstract Whether radiation therapy (RT) affects contralateral breast cancer (CBC) risk in women with pathogenic germline variants in moderate- to high-penetrance breast cancer–associated genes is unknown. In a population-based case-control study, we examined the association between RT; variants in ATM, BRCA1/2, or CHEK2*1100delC; and CBC risk. We analyzed 708 cases of women with CBC and 1399 controls with unilateral breast cancer, all diagnosed with first invasive breast cancer between 1985 and 2000 and aged younger than 55 years at diagnosis and screened for variants in breast cancer–associated genes. Rate ratios (RR) and 95% confidence intervals (CIs) were estimated using multivariable conditional logistic regression. RT did not modify the association between known pathogenic variants and CBC risk (eg, BRCA1/2 pathogenic variant carriers without RT: RR = 3.52, 95% CI = 1.76 to 7.01; BRCA1/2 pathogenic variant carriers with RT: RR = 4.46, 95% CI = 2.96 to 6.71), suggesting that modifying RT plans for young women with breast cancer is unwarranted. Rare ATM missense variants, not currently identified as pathogenic, were associated with increased risk of RT-associated CBC (carriers of ATM rare missense variants of uncertain significance without RT: RR = 0.38, 95% CI = 0.09 to 1.55; carriers of ATM rare missense variants of uncertain significance with RT: RR = 2.98, 95% CI = 1.31 to 6.80). Further mechanistic studies will aid clinical decision-making related to RT.


2018 ◽  
Vol 16 (3) ◽  
pp. 62-71
Author(s):  
Lyudmila A. Gordeeva ◽  
Ilija E. Lojko ◽  
Elena N. Voronina ◽  
Ekaterina E. Kutonova ◽  
Elena G. Polenok ◽  
...  

Background. Breast cancer (BC) is the most common oncological disease in women in the world. The aim of study is to investigate the frequencies of mutations in BRCA1 5382insC (rs80357906), CHEK2 1100delC (rs555607708) and BLM c.1642 C>T (rs200389141) genes and their relationship with the phenotypic features of BC in 104 young age women. Materials and methods. We studied 104 young age women with breast cancer. Typing of mutations BRCA1 5382insC, CHEK2 1100delC and BLM c.1642 C>T genes were performed by real-time PCR followed by melting analysis. Results. The BRCA1 5382insC mutation was detected in 9.6% of BC patients. The BRCA1 5382insC mutation was correlated with the lack of expression of estrogen receptors (χ2 = 18.48, d(f) = 1, p < 0.0001), the HER2/neo tumor receptor (χ2 = 5.61, d(f) = 1, p < 0.02). The BRCA1 5382insC mutation was more often in the “triple negative” BC (χ2 = 17.42, d(f) = 3, p < 0.001). Luminal A subtype of disease was observed the predominantly in non-carriers of the mutation BRCA1 5382insC (sporadic breast cancer). The founder mutations in the CHEK2 1100delC and BLM c.1642 C>T genes were absent in young age women with BC. Conclusion. Our results confirm the high significance of detecting the BRCA1 rs80357906 mutation in young age women with BC for optimization of treatment tactic and for early diagnosis of BC.


2018 ◽  
Vol 22 (4) ◽  
pp. 397-407 ◽  
Author(s):  
Mingming Liang ◽  
Yun Zhang ◽  
Chenyu Sun ◽  
Feras Kamel Rizeq ◽  
Min Min ◽  
...  

2018 ◽  
Vol 36 (15) ◽  
pp. 1513-1520 ◽  
Author(s):  
Anne S. Reiner ◽  
Julia Sisti ◽  
Esther M. John ◽  
Charles F. Lynch ◽  
Jennifer D. Brooks ◽  
...  

Purpose The Women’s Environmental Cancer and Radiation Epidemiology (WECARE) study demonstrated the importance of breast cancer family history on contralateral breast cancer (CBC) risk, even for noncarriers of deleterious BRCA1/2 mutations. With the completion of WECARE II, updated risk estimates are reported. Additional analyses that exclude women negative for deleterious mutations in ATM, CHEK2*1100delC, and PALB2 were performed. Patients and Methods The WECARE Study is a population-based case-control study that compared 1,521 CBC cases with 2,212 individually matched unilateral breast cancer (UBC) controls. Participants were younger than age 55 years when diagnosed with a first invasive breast cancer between 1985 and 2008. Women were interviewed about breast cancer risk factors, including family history. A subset of women was screened for deleterious mutations in BRCA1/2, ATM, CHEK2*1100delC, and PALB2. Rate ratios (RRs) were estimated using multivariable conditional logistic regression. Cumulative absolute risks (ARs) were estimated by combining RRs from the WECARE Study and population-based SEER*Stat cancer incidence data. Results Women with any first-degree relative with breast cancer had a 10-year AR of 8.1% for CBC (95% CI, 6.7% to 9.8%). Risks also were increased if the relative was diagnosed at an age younger than 40 years (10-year AR, 13.5%; 95% CI, 8.8% to 20.8%) or with CBC (10-year AR, 14.1%; 95% CI, 9.5% to 20.7%). These risks are comparable with those seen in BRCA1/2 deleterious mutation carriers (10-year AR, 18.4%; 95% CI, 16.0% to 21.3%). In the subset of women who tested negative for deleterious mutations in BRCA1/2, ATM, CHEK2*1100delC, and PALB2, estimates were unchanged. Adjustment for known breast cancer single-nucleotide polymorphisms did not affect estimates. Conclusion Breast cancer family history confers a high CBC risk, even after excluding women with deleterious mutations. Clinicians are urged to use detailed family histories to guide treatment and future screening decisions for young women with breast cancer.


2018 ◽  
Vol 5 (1) ◽  
pp. 19-23 ◽  
Author(s):  
Joanna Huszno ◽  
Zofia Kołosza

Renal cell carcinoma (RCC) occurs in sporadic and heritable forms. Genetic mutations have been identified as risk factors in 1–2% of RCC. The aim of this study was to evaluate I157T and CHEK2*1100delC mutations of checkpoint kinase 2 (CHEK2) gene in RCC. Medical records of 40 clear cell RCC patients who had genetic tests and consultation at the Genetic Outpatient Clinic, Maria Sk?odowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland, were reviewed retrospectively. Mutation profile was assessed by ASA-PCR and RFLP-PCR techniques. Only three female patients had CHEK2 mutation (I157T). No CHEK2*1100delC was observed in any of the patients. These tumors were N0, and two were Grade 3. One showed capsular infiltration. No blood vessel infiltration or metastases was observed. Overall, RCC from patients with CHEK2 mutation did not display any special characteristics when compared with those without the mutation. While no association between CHEK2 mutation and RCC could be established, all three patients with CHEK2 mutation developed second neoplasms many years after first diagnosis. Further studies, especially regarding CHEK2 mutation as a predictive factor for second neoplasm in RCC patients, are warranted.


2016 ◽  
Vol 19 (5) ◽  
pp. 599-603 ◽  
Author(s):  
Taru A. Muranen ◽  
◽  
Dario Greco ◽  
Carl Blomqvist ◽  
Kristiina Aittomäki ◽  
...  

2016 ◽  
Vol 34 (23) ◽  
pp. 2750-2760 ◽  
Author(s):  
Marjanka K. Schmidt ◽  
Frans Hogervorst ◽  
Richard van Hien ◽  
Sten Cornelissen ◽  
Annegien Broeks ◽  
...  

Purpose CHEK2*1100delC is a well-established breast cancer risk variant that is most prevalent in European populations; however, there are limited data on risk of breast cancer by age and tumor subtype, which limits its usefulness in breast cancer risk prediction. We aimed to generate tumor subtype- and age-specific risk estimates by using data from the Breast Cancer Association Consortium, including 44,777 patients with breast cancer and 42,997 controls from 33 studies genotyped for CHEK2*1100delC. Patients and Methods CHEK2*1100delC genotyping was mostly done by a custom Taqman assay. Breast cancer odds ratios (ORs) for CHEK2*1100delC carriers versus noncarriers were estimated by using logistic regression and adjusted for study (categorical) and age. Main analyses included patients with invasive breast cancer from population- and hospital-based studies. Results Proportions of heterozygous CHEK2*1100delC carriers in controls, in patients with breast cancer from population- and hospital-based studies, and in patients with breast cancer from familial- and clinical genetics center–based studies were 0.5%, 1.3%, and 3.0%, respectively. The estimated OR for invasive breast cancer was 2.26 (95%CI, 1.90 to 2.69; P = 2.3 × 10−20). The OR was higher for estrogen receptor (ER)–positive disease (2.55 [95%CI, 2.10 to 3.10; P = 4.9 × 10−21]) than it was for ER-negative disease (1.32 [95%CI, 0.93 to 1.88; P = .12]; P interaction = 9.9 × 10−4). The OR significantly declined with attained age for breast cancer overall (P = .001) and for ER-positive tumors (P = .001). Estimated cumulative risks for development of ER-positive and ER-negative tumors by age 80 in CHEK2*1100delC carriers were 20% and 3%, respectively, compared with 9% and 2%, respectively, in the general population of the United Kingdom. Conclusion These CHEK2*1100delC breast cancer risk estimates provide a basis for incorporating CHEK2*1100delC into breast cancer risk prediction models and into guidelines for intensified screening and follow-up.


Sign in / Sign up

Export Citation Format

Share Document